A detailed history of Moody Lynn & Lieberson, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Moody Lynn & Lieberson, LLC holds 23,029 shares of BMY stock, worth $1.33 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
23,029
Previous 8,325 176.62%
Holding current value
$1.33 Million
Previous $345,000 245.22%
% of portfolio
0.08%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$39.66 - $51.75 $583,160 - $760,932
14,704 Added 176.62%
23,029 $1.19 Million
Q2 2024

Jul 25, 2024

SELL
$40.25 - $52.99 $1.7 Million - $2.23 Million
-42,144 Reduced 83.5%
8,325 $345,000
Q1 2024

Apr 23, 2024

SELL
$47.98 - $54.4 $9.49 Million - $10.8 Million
-197,747 Reduced 79.67%
50,469 $2.74 Million
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $3.05 Million - $3.64 Million
-62,882 Reduced 20.21%
248,216 $12.7 Million
Q3 2023

Oct 24, 2023

SELL
$57.89 - $64.73 $331,536 - $370,708
-5,727 Reduced 1.81%
311,098 $18.1 Million
Q2 2023

Jul 27, 2023

BUY
$63.71 - $70.74 $211,198 - $234,503
3,315 Added 1.06%
316,825 $20.3 Million
Q1 2023

May 02, 2023

SELL
$65.71 - $74.53 $422,449 - $479,153
-6,429 Reduced 2.01%
313,510 $21.7 Million
Q4 2022

Feb 01, 2023

SELL
$68.48 - $81.09 $22,324 - $26,435
-326 Reduced 0.1%
319,939 $23 Million
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $5,409 - $3.2 Million
-41,614 Reduced 11.5%
320,265 $22.8 Million
Q2 2022

Jul 28, 2022

SELL
$72.62 - $79.98 $3.23 Million - $3.56 Million
-44,531 Reduced 10.96%
361,879 $27.9 Million
Q1 2022

Apr 27, 2022

BUY
$61.48 - $73.72 $1.99 Million - $2.39 Million
32,444 Added 8.68%
406,410 $29.7 Million
Q4 2021

Jan 26, 2022

BUY
$53.63 - $62.52 $2.15 Million - $2.51 Million
40,121 Added 12.02%
373,966 $23.3 Million
Q3 2021

Oct 26, 2021

SELL
$59.17 - $69.31 $277,862 - $325,479
-4,696 Reduced 1.39%
333,845 $19.8 Million
Q2 2021

Jul 28, 2021

BUY
$61.91 - $67.42 $1.7 Million - $1.86 Million
27,536 Added 8.85%
338,541 $22.6 Million
Q1 2021

Apr 23, 2021

SELL
$59.34 - $66.74 $753,677 - $847,664
-12,701 Reduced 3.92%
311,005 $19.6 Million
Q4 2020

Jan 26, 2021

BUY
$57.74 - $65.43 $203,013 - $230,051
3,516 Added 1.1%
323,706 $20.1 Million
Q3 2020

Oct 28, 2020

SELL
$57.43 - $63.64 $351,701 - $389,731
-6,124 Reduced 1.88%
320,190 $19.3 Million
Q2 2020

Jul 24, 2020

BUY
$54.82 - $64.09 $2.48 Million - $2.9 Million
45,247 Added 16.1%
326,314 $19.2 Million
Q1 2020

Apr 30, 2020

SELL
$46.4 - $67.43 $2.68 Million - $3.89 Million
-57,750 Reduced 17.04%
281,067 $15.7 Million
Q4 2019

Jan 28, 2020

BUY
$49.21 - $64.19 $7.4 Million - $9.65 Million
150,379 Added 79.8%
338,817 $21.7 Million
Q3 2019

Oct 28, 2019

SELL
$42.77 - $50.71 $2.98 Million - $3.53 Million
-69,632 Reduced 26.98%
188,438 $9.56 Million
Q2 2019

Jul 23, 2019

SELL
$44.62 - $49.34 $762,109 - $842,727
-17,080 Reduced 6.21%
258,070 $11.7 Million
Q1 2019

Apr 23, 2019

BUY
$45.12 - $53.8 $1.14 Million - $1.36 Million
25,344 Added 10.15%
275,150 $13.1 Million
Q4 2018

Jan 29, 2019

BUY
$48.76 - $63.23 $11.3 Million - $14.7 Million
232,027 Added 1305.06%
249,806 $13 Million
Q3 2018

Oct 29, 2018

BUY
$55.19 - $62.25 $1,986 - $2,241
36 Added 0.2%
17,779 $1.1 Million
Q2 2018

Jul 24, 2018

SELL
$50.53 - $62.98 $31,682 - $39,488
-627 Reduced 3.41%
17,743 $982,000
Q1 2018

Apr 27, 2018

BUY
$59.92 - $68.98 $89,041 - $102,504
1,486 Added 8.8%
18,370 $1.16 Million
Q4 2017

Feb 02, 2018

SELL
$59.94 - $65.35 $5,394 - $5,881
-90 Reduced 0.53%
16,884 $1.08 Million
Q3 2017

Nov 06, 2017

BUY
$55.23 - $63.74 $937,474 - $1.08 Million
16,974
16,974 $1.08 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Moody Lynn & Lieberson, LLC Portfolio

Follow Moody Lynn & Lieberson, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moody Lynn & Lieberson, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Moody Lynn & Lieberson, LLC with notifications on news.